H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall St set for muted open as tech wobble persists; Tesla gains
- Oil heads for weekly gain with focus on Middle East supply
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 121.51 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $121.51 | 52 Week High | $18.39 | |||
| Open | $121.51 | 52 Week Low | $6.96 | |||
| Day High | $121.51 | P/E | N/A | |||
| Day Low | $121.51 | EPS | $-0.58 | |||
| Volume | 1,232 | |||||
